Co-Diagnostics, Inc. (0A50.L)

1,1500 +0,0200 (+1,77%) Alla chiusura: 04:31PM BST

Co-Diagnostics, Inc.

2401 South Foothill Drive
Suite D
Salt Lake City, UT 84109
United States
(801) 438-1036
https://www.codiagnostics.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 155

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Dwight H. Egan	Chairman & CEO	415,75k	N/D	1953
Mr. Brian L. Brown CPA	CFO & Company Secretary	338,92k	N/D	1976
Mr. Richard David Abbott	President	N/D	N/D	1972
Dr. Brent C. Satterfield Ph.D.	Co-Founder & Member of Scientific Advisory Board	237,5k	N/D	1977
Mr. David Nielsen	Chief Operating Officer	N/D	N/D	N/D
Mr. Dan Bohrer CPA	Vice President of Finance & Accounting	N/D	N/D	N/D
Mr. Christopher Thurston	Chief Technology Officer	N/D	N/D	N/D
Dr. Mark Poritz Ph.D.	Chief Scientific Officer	N/D	N/D	N/D
Mr. Andrew Benson	Head of Investor Relations	N/D	N/D	N/D
Dr. Mayuranki Almaula	Senior Vice President of Overseas Operations & Strategic Alliances	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Governance aziendale

L'ISS Governance QualityScore di Co-Diagnostics, Inc. al 1 aprile 2024 è 9. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 10; diritti degli azionisti: 5; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.